Mariam Imnadze1, Daniel D Sjoberg2, Andrew J Vickers2. 1. Urology Service, Department of Surgery, Sidney Kimmel Center for Prostate and Urologic Cancers, New York, NY, USA. Electronic address: imnadzem@mskcc.org. 2. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Abstract
BACKGROUND: Up to 30% of patients with low-risk prostate cancer (PCa) are found to have features of aggressive disease at radical prostatectomy (RP). Several predictive nomograms and novel genomic markers have been developed to estimate the risk of adverse pathology in men eligible for active surveillance (AS). However, oncologic risk associated with these findings remains unknown. OBJECTIVE: To determine if the presence of adverse pathologic features at RP in patients eligible for AS is prognostic of poor oncologic outcome independent of pretreatment risk status. DESIGN, SETTING, AND PARTICIPANTS: A total of 2660 patients underwent immediate RP at our institution between 1998 and 2008. Patients were stratified as low, intermediate, or high risk according to the D'Amico clinical risk criteria. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The rates of adverse pathology were reported, and the 5-yr risk of biochemical recurrence (BCR) was calculated in the presence of aggressive disease. RESULTS AND LIMITATIONS: The 5-yr risk of BCR in patients with extracapsular extension (n=937) was 43% (95% confidence interval [CI], 40-46) overall but only 15% (95% CI, 11-22) for those who met the criteria for low risk (n=181). For the 473 patients with pathologic Gleason score 4+3, the risk of recurrence at 5 yr was 41% (95% CI, 37-46) overall, 13% (95% CI, 5-27) for low-risk men (n=41), 41% (95% CI, 35-47) for intermediate-risk men (n=287), and 51% (95% CI, 43-60) for high-risk men (n=145). Limitations include use of BCR as the study end point and surrogate for oncologic outcome in men who received curative treatment. CONCLUSIONS: The presence of pathologically unfavorable disease in patients eligible for AS is not informative as to the safety of this treatment modality. We question the relevance of adverse pathology as the end point for predictive tools designed to guide treatment decisions in low-risk PCa. PATIENT SUMMARY: The risk of biochemical recurrence associated with adverse pathologic findings at prostatectomy is reduced by approximately 50% in men with clinically low-risk prostate cancer.
BACKGROUND: Up to 30% of patients with low-risk prostate cancer (PCa) are found to have features of aggressive disease at radical prostatectomy (RP). Several predictive nomograms and novel genomic markers have been developed to estimate the risk of adverse pathology in men eligible for active surveillance (AS). However, oncologic risk associated with these findings remains unknown. OBJECTIVE: To determine if the presence of adverse pathologic features at RP in patients eligible for AS is prognostic of poor oncologic outcome independent of pretreatment risk status. DESIGN, SETTING, AND PARTICIPANTS: A total of 2660 patients underwent immediate RP at our institution between 1998 and 2008. Patients were stratified as low, intermediate, or high risk according to the D'Amico clinical risk criteria. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The rates of adverse pathology were reported, and the 5-yr risk of biochemical recurrence (BCR) was calculated in the presence of aggressive disease. RESULTS AND LIMITATIONS: The 5-yr risk of BCR in patients with extracapsular extension (n=937) was 43% (95% confidence interval [CI], 40-46) overall but only 15% (95% CI, 11-22) for those who met the criteria for low risk (n=181). For the 473 patients with pathologic Gleason score 4+3, the risk of recurrence at 5 yr was 41% (95% CI, 37-46) overall, 13% (95% CI, 5-27) for low-risk men (n=41), 41% (95% CI, 35-47) for intermediate-risk men (n=287), and 51% (95% CI, 43-60) for high-risk men (n=145). Limitations include use of BCR as the study end point and surrogate for oncologic outcome in men who received curative treatment. CONCLUSIONS: The presence of pathologically unfavorable disease in patients eligible for AS is not informative as to the safety of this treatment modality. We question the relevance of adverse pathology as the end point for predictive tools designed to guide treatment decisions in low-risk PCa. PATIENT SUMMARY: The risk of biochemical recurrence associated with adverse pathologic findings at prostatectomy is reduced by approximately 50% in men with clinically low-risk prostate cancer.
Authors: Jean-Baptiste Beauval; Guillaume Ploussard; Michel Soulié; Christian Pfister; Simon Van Agt; Sébastien Vincendeau; Sébastien Larue; Jérome Rigaud; Nicolas Gaschignard; Morgan Rouprêt; Sarah Drouin; Mickael Peyromaure; Jean Alexandre Long; Francois Iborra; Guy Vallancien; Francois Rozet; Laurent Salomon Journal: Urology Date: 2012-07-07 Impact factor: 2.649
Authors: Stephen J Freedland; Elizabeth B Humphreys; Leslie A Mangold; Mario Eisenberger; Frederick J Dorey; Patrick C Walsh; Alan W Partin Journal: JAMA Date: 2005-07-27 Impact factor: 56.272
Authors: Michel Bolla; Hein van Poppel; Laurence Collette; Paul van Cangh; Kris Vekemans; Luigi Da Pozzo; Theo M de Reijke; Antony Verbaeys; Jean-François Bosset; Roland van Velthoven; Jean-Marie Maréchal; Pierre Scalliet; Karin Haustermans; Marianne Piérart Journal: Lancet Date: 2005 Aug 13-19 Impact factor: 79.321
Authors: Matthew Truong; Jon A Slezak; Chee Paul Lin; Viacheslav Iremashvili; Martins Sado; Aria A Razmaria; Glen Leverson; Mark S Soloway; Scott E Eggener; E Jason Abel; Tracy M Downs; David F Jarrard Journal: Cancer Date: 2013-09-04 Impact factor: 6.860
Authors: Marc A Dall'Era; Peter C Albertsen; Christopher Bangma; Peter R Carroll; H Ballentine Carter; Matthew R Cooperberg; Stephen J Freedland; Laurence H Klotz; Christopher Parker; Mark S Soloway Journal: Eur Urol Date: 2012-06-07 Impact factor: 20.096
Authors: A V D'Amico; R Whittington; S B Malkowicz; D Schultz; K Blank; G A Broderick; J E Tomaszewski; A A Renshaw; I Kaplan; C J Beard; A Wein Journal: JAMA Date: 1998-09-16 Impact factor: 56.272
Authors: Matthew R Cooperberg; Jeffry P Simko; Janet E Cowan; Julia E Reid; Azita Djalilvand; Satish Bhatnagar; Alexander Gutin; Jerry S Lanchbury; Gregory P Swanson; Steven Stone; Peter R Carroll Journal: J Clin Oncol Date: 2013-03-04 Impact factor: 44.544
Authors: Eric A Klein; Matthew R Cooperberg; Cristina Magi-Galluzzi; Jeffry P Simko; Sara M Falzarano; Tara Maddala; June M Chan; Jianbo Li; Janet E Cowan; Athanasios C Tsiatis; Diana B Cherbavaz; Robert J Pelham; Imelda Tenggara-Hunter; Frederick L Baehner; Dejan Knezevic; Phillip G Febbo; Steven Shak; Michael W Kattan; Mark Lee; Peter R Carroll Journal: Eur Urol Date: 2014-05-16 Impact factor: 20.096
Authors: Anouk A M A van der Aa; Christophe K Mannaerts; Hans van der Linden; Maudy Gayet; Bart Ph Schrier; Massimo Mischi; Harrie P Beerlage; Hessel Wijkstra Journal: World J Urol Date: 2018-02-01 Impact factor: 4.226
Authors: François Audenet; Emily A Vertosick; Samson W Fine; Daniel D Sjoberg; Andrew J Vickers; Victor E Reuter; James A Eastham; Peter T Scardino; Karim A Touijer Journal: J Urol Date: 2017-10-10 Impact factor: 7.450
Authors: Robert T Dess; Todd M Morgan; Paul L Nguyen; Rohit Mehra; Howard M Sandler; Felix Y Feng; Daniel E Spratt Journal: Curr Urol Rep Date: 2017-07 Impact factor: 3.092
Authors: Andreas G Wibmer; Ines Nikolovski; Joshua Chaim; Yulia Lakhman; Robert A Lefkowitz; Evis Sala; Sigrid V Carlsson; Samson W Fine; Michael W Kattan; Hedvig Hricak; Hebert Alberto Vargas Journal: Radiology Date: 2021-12-21 Impact factor: 11.105
Authors: Lucas W Dean; Melissa Assel; Daniel D Sjoberg; Andrew J Vickers; Hikmat A Al-Ahmadie; Ying-Bei Chen; Anuradha Gopalan; S Joseph Sirintrapun; Satish K Tickoo; James A Eastham; Peter T Scardino; Victor E Reuter; Behfar Ehdaie; Samson W Fine Journal: J Urol Date: 2019-01 Impact factor: 7.450
Authors: Lars A R Reisæter; Jurgen J Fütterer; Are Losnegård; Yngve Nygård; Jan Monssen; Karsten Gravdal; Ole J Halvorsen; Lars A Akslen; Martin Biermann; Svein Haukaas; Jarle Rørvik; Christian Beisland Journal: Eur Radiol Date: 2017-10-06 Impact factor: 5.315
Authors: Won Sik Jang; Lawrence H C Kim; Cheol Yong Yoon; Koon Ho Rha; Young Deuk Choi; Sung Joon Hong; Won Sik Ham Journal: PLoS One Date: 2016-10-07 Impact factor: 3.240